Research ExplorerPublicationsCOPD: leitliniengerechte Therapie (Modifizierter Nachdruck a...

COPD: leitliniengerechte Therapie (Modifizierter Nachdruck aus MMP)

Standard

COPD: leitliniengerechte Therapie (Modifizierter Nachdruck aus MMP). / Paparoupa, Maria; Gillissen, Adrian.

In: Arzneimitteltherapie, Vol. Heft 3, No. 2018;36, 03.03.2018, p. 56–62.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Transfer

Harvard

Paparoupa, M & Gillissen, A 2018, 'COPD: leitliniengerechte Therapie (Modifizierter Nachdruck aus MMP)', Arzneimitteltherapie, vol. Heft 3, no. 2018;36, pp. 56–62.

APA

Paparoupa, M., & Gillissen, A. (2018). COPD: leitliniengerechte Therapie (Modifizierter Nachdruck aus MMP). Arzneimitteltherapie, Heft 3(2018;36), 56–62.

Vancouver

Paparoupa M, Gillissen A. COPD: leitliniengerechte Therapie (Modifizierter Nachdruck aus MMP). Arzneimitteltherapie. 2018 Mar 3;Heft 3(2018;36):56–62.

Bibtex

@article{3495a486697e45458f8dd12e19694ce5,
title = "COPD: leitliniengerechte Therapie (Modifizierter Nachdruck aus MMP)",
abstract = "The pillars of the pharmacologic treatment in chronic obstructive pulmonary disease (COPD) consist of an inhaled long-acting muscarinic antagonist (LAMA) or a long-acting β2-agonist (LABA) or the combination of both. The inhaled corticosteroid (ICS)/LABA-combination is only indicated to prevent exacerbations. In 07/2017 a new fixed triple combination containing beclometasone/formoterol/glycopyrronium has been approved for moderate to severe COPD patients. This paper puts new treatment paradigms in the management of COPD such as tentative use of ICS into perspective and further discusses other pharmacological options such as roflumilast and mucolytic drugs.",
author = "Maria Paparoupa and Adrian Gillissen",
year = "2018",
month = mar,
day = "3",
language = "Deutsch",
volume = "Heft 3",
pages = "56–62",
number = "2018;36",

}

RIS

TY - JOUR

T1 - COPD: leitliniengerechte Therapie (Modifizierter Nachdruck aus MMP)

AU - Paparoupa, Maria

AU - Gillissen, Adrian

PY - 2018/3/3

Y1 - 2018/3/3

N2 - The pillars of the pharmacologic treatment in chronic obstructive pulmonary disease (COPD) consist of an inhaled long-acting muscarinic antagonist (LAMA) or a long-acting β2-agonist (LABA) or the combination of both. The inhaled corticosteroid (ICS)/LABA-combination is only indicated to prevent exacerbations. In 07/2017 a new fixed triple combination containing beclometasone/formoterol/glycopyrronium has been approved for moderate to severe COPD patients. This paper puts new treatment paradigms in the management of COPD such as tentative use of ICS into perspective and further discusses other pharmacological options such as roflumilast and mucolytic drugs.

AB - The pillars of the pharmacologic treatment in chronic obstructive pulmonary disease (COPD) consist of an inhaled long-acting muscarinic antagonist (LAMA) or a long-acting β2-agonist (LABA) or the combination of both. The inhaled corticosteroid (ICS)/LABA-combination is only indicated to prevent exacerbations. In 07/2017 a new fixed triple combination containing beclometasone/formoterol/glycopyrronium has been approved for moderate to severe COPD patients. This paper puts new treatment paradigms in the management of COPD such as tentative use of ICS into perspective and further discusses other pharmacological options such as roflumilast and mucolytic drugs.

UR - https://www.arzneimitteltherapie.de/archiv/ausgabe/2018/03.html

M3 - SCORING: Zeitschriftenaufsatz

VL - Heft 3

SP - 56

EP - 62

IS - 2018;36

ER -